Literature DB >> 27446461

Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells.

Lucyna Kapka-Skrzypczak1, Sylwia Popek2, Krzysztof Sawicki2, Ewa Wolińska3, Magdalena Czajka2, Maciej Skrzypczak4.   

Abstract

The aim of the present study was to evaluate the role of interleukin (IL)-6 and IL-8 on the expression of the membrane-bound complement inhibitors membrane attack complex-inhibitory protein (CD59) and decay-accelerating factor (CD55), in the human ovarian carcinoma A2780 cell line, which is a non-producing IL-6 cell line that does exhibit IL-6 responsiveness, due to the presence of IL-6 receptors. Extracellular levels of complement system inhibitors were evaluated by western blotting and reverse transcription-quantitative polymerase chain reaction. Cellular localization of CD55 and CD59 in the ovarian cancer cells was assessed by immunofluorescence. The detection of a soluble form of CD55 and CD59 released by the A2780 cells following stimulation with IL-6 and IL-8 was detected by enzyme-linked immunosorbent assay. The present data revealed that A2780 cells express CD55 and CD59 at the mRNA and protein level, but do not secrete these proteins to the culture medium. Results of western blotting demonstrated that the protein level of CD59 was regulated by IL-6 and IL-8 in a dose-dependent manner. Immunofluorescence analysis revealed that the ovarian cancer A2780 cell line expresses the membrane bound form of CD55 protein. The present results indicate that CD55 and CD59 may affect the efficiency of complement-mediated immunotherapies.

Entities:  

Keywords:  CD55; CD59; IL-6; complement system; ovarian cancer

Year:  2016        PMID: 27446461      PMCID: PMC4950665          DOI: 10.3892/ol.2016.4795

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  13 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells.

Authors:  Yue Wang; Jie Yang; Yan Gao; Yongrui Du; Leyuan Bao; Wenyan Niu; Zhi Yao
Journal:  Cell Mol Immunol       Date:  2005-10       Impact factor: 11.530

Review 3.  Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.

Authors:  Benoît Thibault; Magali Castells; Jean-Pierre Delord; Bettina Couderc
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

4.  Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines.

Authors:  J G Asschert; E Vellenga; M H Ruiters; E G de Vries
Journal:  Int J Cancer       Date:  1999-07-19       Impact factor: 7.396

Review 5.  Ovarian cancer: diagnostic, biological and prognostic aspects.

Authors:  Ben Davidson; Claes G Tropé
Journal:  Womens Health (Lond)       Date:  2014-09

6.  Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.

Authors:  Justyna Dzietczenia; Tomasz Wróbel; Grzegorz Mazur; Rafał Poreba; Bozena Jaźwiec; Kazimierz Kuliczkowski
Journal:  Med Oncol       Date:  2009-08-07       Impact factor: 3.064

Review 7.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

8.  A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Authors:  Hagen Kulbe; Probir Chakravarty; D Andrew Leinster; Kellie A Charles; Joseph Kwong; Richard G Thompson; Jermaine I Coward; Tiziana Schioppa; Stephen C Robinson; William M Gallagher; Laura Galletta; Michael A Salako; John F Smyth; Thorsten Hagemann; Donal J Brennan; David D Bowtell; Frances R Balkwill
Journal:  Cancer Res       Date:  2011-11-07       Impact factor: 12.701

9.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

10.  Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Authors:  Corine M Beaufort; Jean C A Helmijr; Anna M Piskorz; Marlous Hoogstraat; Kirsten Ruigrok-Ritstier; Nicolle Besselink; Muhammed Murtaza; Wilfred F J van IJcken; Anouk A J Heine; Marcel Smid; Marco J Koudijs; James D Brenton; Els M J J Berns; Jozien Helleman
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

View more
  2 in total

1.  iTRAQ-based Comparative Serum Proteomic Analysis of Prostate Cancer Patients with or without Bone Metastasis.

Authors:  Bo Yan; Binshen Chen; Shaoju Min; Yubo Gao; Yiming Zhang; Peng Xu; Chaoming Li; Jiasheng Chen; Guangheng Luo; Chunxiao Liu
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207

2.  Urinary Proteomics of Simulated Firefighting Tasks and Its Relation to Fitness Parameters.

Authors:  Ting Zhu; Yuxiang Hu; Jooyeon Hwang; Dan Zhao; Libin Huang; Liang Qiao; Ankui Wei; Xin Xu
Journal:  Int J Environ Res Public Health       Date:  2021-10-11       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.